Dr. Jaume Capdevila
Address: Carrer de Vilana, 12, 08022 Barcelona, Barcelona, Catalunya, Spain
Gender: Male
About the Doctor / Professional
Dr. Jaume Capdevila, MD, PhD, serves as a senior medical oncologist at Vall d'Hebron University Hospital and as a senior clinical and translational researcher at Vall d'Hebron Institute of Oncology (VHIO) in Barcelona. He is actively engaged in both research and the treatment of patients with gastrointestinal cancer, leading the unit dedicated to endocrine and neuroendocrine tumors. Additionally, he plays a key role in early drug development, with a focus on neoplasms within his expertise.
Within Medical Oncology, his area of specialization is the systematic treatment of tumors of the digestive tract (esophagus-gastric, colorectal, pancreatic, bile duct, liver, small intestine, peritoneal and anal canal) and tumors of the endocrine area (thyroid, gastroenteropancreatic neuroendocrine, paragangliomas, pheochromocytomas, adrenal carcinoma, and tumors of other origins of neuroendocrine lineage).
Dr. Capdevila has an extensive publication record, with over 250 articles in peer-reviewed journals, and he is at the forefront of national and international clinical trials.
Degree: Universitat de Lleida
Residency: Universitat Autònoma de Barcelona
- 2013 – Present: Head of Gastrointestinal and Endocrine Tumor Unit - Teknon Oncology Institute
- 2006 – Present: Clinical oncologist - Institute of Oncology, Hospital Quirónsalud Barcelona
- 2006 – Present: Medical Oncologist- Vall d'Hebron University Hospital
- 2002 – 2006: Medical Oncologist - Hospital de la Santa Creu i Sant Pau
- S Singh; D Halperin; S Myrehaug; K Herrmann; M Pavel; PL Kunz; B Chasen; S Tafuto; S Lastoria; J Capdevila; A García-Burillo; DY Oh; C Yoo; TR Halfdanarson; S Falk; I Folitar; Y Zhang; P Aimone; WW de Herder; D Ferone.
- 177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.Lancet.6736 - 24, pp. S0140. 05/06/2024. DOI: 10.1016/S0140-6736(24)00701-3.
- A Koumarianou; PL Filosso; L Bodei; JP Castano; L Fernandez-Cuesta; CM Deroose; M Foll; C Dromain; NS Reed; M Caplin; J Capdevila; J Falkerby; A Faggiano; A Frilling; E Grande; RJ Hicks; A Kasajima; B Kos-Kudla; BA Krishna; E Lim; A Rinke; S Singh; C Thirlwell; M Volante; T Walter. Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force.J Neuroendocrinol.pp. e13412. 16/05/2024.
- S Singh; D Ferone; J Capdevila; JA Chan; WW de Herder; D Halperin; J Mailman; L Hellström; H Liedman; A Svedberg; F Tiberg. Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.Trials.25 - 1, pp. 297. 02/05/2024.
- J Hernando; M Roca-Herrera; A García-Álvarez; E Raymond; P Ruszniewski; MH Kulke; E Grande; RG Carbonero; D Castellano; R Salazar; T Ibrahim; A Teule; V Alonso; N Fazio; JW Valle; S Tafuto; A Carmona; V Navarro; J Capdevila. Corrigendum to : Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours.Eur J Cancer.188, pp. 39 - 48. 04/2024.
- O Prior; C Macarro; V Navarro; C Monreal; M Ligero; A Garcia-Ruiz; G Serna; S Simonetti; I Braña; M Vieito; M Escobar; J Capdevila; AT Byrne; R Dienstmann; R Toledo; P Nuciforo; E Garralda; F Grussu; K Bernatowicz; R Perez-Lopez. Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer.Radiol Artif Intell.6 - 2, pp. e230118. 03/2024
- PB Romesser; J Capdevila; R Garcia-Carbonero; T Philip; C Fernandez Martos; R Tuli; A Rodriguez-Gutierrez; M Kuipers; A Becker; A Coenen-Stass; B Sarholz; X You; ED. Miller. A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.Clin Cancer Res.30 - 4, pp. 695 - 702. 16/02/2024.
- S Singh; D Ferone; J Capdevila; JA Chan; WW de Herder; D Halperin; J Mailman; L Hellström; H Liedman; A Svedberg; F Tiberg. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.Trials.25 - 1, pp. 58. 16/01/2024.
- A La Salvia; A Lens-Pardo; A López-López; C Carretero-Puche; J Capdevila; M Benavent; P Jiménez-Fonseca; D Castellano; T Alonso; A Teule; A Custodio; S Tafuto; A La Casta; F Spada; A Lopez-Gonzalvez; B Gil-Calderon; P Espinosa-Olarte; C Barbas; R Garcia-Carbonero; B Soldevilla. Metabolomic profile of neuroendocrine tumors (NETs) identifies methionine, porphyrin and tryptophan metabolism as key dysregulated pathways associated with patient survival.Eur J Endocrinol.01/2024
- J Capdevila; J Krajewska; J Hernando; B Robinson; SI Sherman; B Jarzab; CC Lin; F Vaisman; AO Hoff; E Hitre; D Bowles; D Williamson; R Levytskyy; JW Oliver; B Keam; M Brose. Increased progression-free survival with cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer irrespective of prior VEGFR-targeted therapy and tumor histology: a subgroup analysis of the COSMIC-311 study.Thyroid. 07/12/2023.
- D Pesántez; S Ten Hoorn; I Machado; X García-Albéniz; N Rodríguez-Salas; V Heredia-Soto; D Viñal; C Pericay; R García-Carbonero; B Losa; V Alonso; R Vera; J Feliu Batlle; J Gallego; A Salud; M Nogué; L Layos; C Montagut; J Capdevila; L Vermeulen; J Maurel; C Fernandez-Martos. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.J Natl Cancer Inst.115 - 12, pp. 1497 - 1505. 06/12/2023.
- J Hadoux; R Elisei; MS Brose; AO Hoff; BG Robinson; M Gao; B Jarzab; P Isaev; K Kopeckova; J Wadsley; D Führer; B Keam; S Bardet; EJ Sherman; M Tahara; Hu MI; R Singh; Y Lin; V Soldatenkova; J Wright; B Lin; P Maeda; J Capdevila; LJ Wirth. LIBRETTO-531 Trial Investigators. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.N Engl J Med.20 - 20, pp. 1851 - 1861. 16/11/2023.
- EA Dijkstra; PJ Nilsson; GAP Hospers; RR Bahadoer; E Meershoek-Klein Kranenbarg; AGH Roodvoets; H Putter; A Berglund; A Cervantes; Crolla RMPH; MP Hendriks; J Capdevila; I Edhemovic; CAM Marijnen; CJH van de Velde; B Glimelius; B van Etten. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial.Ann Surg.278 - 4, pp. e766 - e772. 01/10/2023.
- N Andreatos; PW McGarrah; MB Sonbol; JS Starr; J Capdevila; H Sorbye; TR Halfdanarson. Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment.Curr Oncol Rep.25 - 10, pp. 1127 - 1139. 01/10/2023.
- JC Castillón; TA Gordoa; AC Bayonas; AC Carretero; R García-Carbonero; EG Pulido; PJ Fonseca; AL Lete; AS Huerta; JG Plazas. SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs). Clin Transl Oncol.25 - 9, pp. 2692 - 2706. 09/2023.
- E Grande; F Moreno; J Trigo; J Capdevila; J Abilés; M Sirvent; M Garrido-Siles; G Olveira; J Ocón; MLF Soto. Expert design thinking workshops to analyze users perceived applicability of NUTRI-ONCOCARE algorithm to prevent and treat malnutrition in cancer patients under routine clinical practice conditions in Spain: the ALLIANCE study.Support Care Cancer.31 - 9, pp. 548. 09/2023
- E Cuesta-Borràs; C Salvans; O Arqués; I Chicote; L Ramírez; L Cabellos; J Martínez-Quintanilla; A Mur-Espinosa; A García-Álvarez; J Hernando; JR Tejedor; O Mirallas; E Elez; MF Fraga; J Tabernero; P Nuciforo; J Capdevila; HG Palmer; I Puig. DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype.Cell Rep.42 - 8, 29/08/2023
- D Pesántez; S Ten Hoorn; I Machado; X García-Albéniz; N Rodríguez-Salas; V Heredia-Soto; D Viñal; C Pericay; R García-Carbonero; F Losa; V Alonso; R Vera; J Feliu Batlle; J Gallego; A Salud; M Nogué; L Layos; C Montagut; J Capdevila; L Vermeulen; J Maurel; C Fernandez-Martos. Total neoadjuvant therapy with or without aflibercept in rectal cancer: Three-year results of GEMCAD-1402.J Natl Cancer Inst.05/07/2023.
- J Capdevila; D Deandreis; C Durante; S Leboulleux; M Luster; R Netea-Maier; K Newbold; S Singer; GP Sykiotis; B Bartes; K Farnell; LD. Locati. Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice.Eur Thyroid J.01/07/2023.
- Jorge Hernando; Maria Roca-Herrera; Alejandro García-Álvarez; Eric Raymond; Philippe Ruszniewski; Matthew H. Kulke; Enrique Grande; Rocío García-Carbonero; Daniel Castellano; Ramón Salazar; Toni Ibrahim; Alex Teule; Vicente Alonso; Fazio l Nicola; Juan W. Valle; Salvatore Tafuto; Ana Carmona; Victor Navarro; Jaume Capdevila. Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours. European Journal of Cancer. 188, pp. 39 - 48. 07/2023.
- I Baraibar; A García; F Salvà; J Ros; N Saoudi; R Comas; G Castillo; M Sanchis; A García-Álvarez; J Hernando; J Capdevila; MR Castells; M Martí; S Landolfi; E Espín; B Navalpotro; J Guevara; C Dopazo; P Nuciforo; A Vivancos; E Élez. Impact of the COVID-19 pandemic in the early-onset colorectal cancer.Transl Oncol.32, 01/06/2023.
- J Capdevila; J Hernando; A Teule; C Lopez; R Garcia-Carbonero; M Benavent; A Custodio; A Garcia-Alvarez; A Cubillo; V Alonso; A Carmona-Bayonas; T Alonso-Gordoa; G Crespo; P Jimenez-Fonseca; M Blanco; A Viudez; A La Casta; I Sevilla; A Segura; M Llanos; S Landolfi; P Nuciforo; JL Manzano. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.Nat Commun.14 -1, pp. 2973. 23/05/2023.
- Rossella Elisei; Enrique Grande; Michael C Kreissl; Sophie Leboulleux; Tarun Puri; Nicolas Fasnacht; Jaume Capdevila. Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe. Front. Oncol.13, 05/2023.
- DY Oh; A Algazi; J Capdevila; F Longo; W Jr Miller; JT Chun Bing; CE Bonilla; HC Chung; TK Guren; CC Lin; D Motola-Kuba; M Shah; J Hadoux; L Yao; F Jin; K Norwood; L Lebellec. Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. Cancer.15/04/2023.
- EA Dijkstra; WH Zwart; PJ Nilsson; H Putter; AGH Roodvoets; E Meershoek-Klein Kranenbarg; JE Frödin; P Nygren; L Østergaard; C Kersten; I Verbiené; A Cervantes; MP Hendriks; J Capdevila; I Edhemovic; CJH van de Velde; CAM Marijnen; B van Etten; GAP Hospers; B Glimelius. The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial.ESMO Open.8 - 2, 03/03/2023.
- PJ Nilsson; GAP Hospers; RR Bahadoer; E Meershoek-Klein Kranenbarg; AGH Roodvoets; H Putter; Å Berglund; A Cervantes; RMPH Crolla; MP Hendriks; J Capdevila; I Edhemovic; CAM Marijnen; CJH Van de Velde; B Glimelius; B van Etten. Locoregional Failure During and After Short-course Radiotherapy followed by Chemotherapy and Surgery Compared to Long-course Chemoradiotherapy and Surgery - A Five-year Follow-up of the RAPIDO Trial.Ann Surg.20/01/2023
- MS Brose; BG Robinson; SI Sherman; B Jarzab; CC Lin; F Vaisman; AO Hoff; E Hitre; DW Bowles; S Sen; JW Oliver; K Banerjee; B Keam; J Capdevila. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer .128 - 24, pp. 4203 - 4212. 15/12/2022.
- J Aparicio; AC Virgili Manrique; J Capdevila; F Muñoz Boza; P Galván; P Richart; H Oliveres; D Páez; J Hernando; S Serrano; R Vera; X Hernandez-Yagüe; RÁ Gallego; MC Riesco-Martinez; X García de Albeniz; J Maurel. Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).Clin Transl Oncol.24 - 11, pp. 2155 - 2165. 11/2022
- A Hollebecque; S Salvagni; R Plummer; P Niccoli; J Capdevila; G Curigliano; V Moreno; F de Braud; SG de Villambrosia; P Martin-Romano; E Baudin; M Arias; J de Alvaro; JL Parra-Palau; T Sánchez-Pérez; I Aronchik; EH Filvaroff; M Lamba; Z Nikolova; JS. de Bono. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.Cancer. 128 - 17, pp. 3185 - 3195. 01/09/2022.
- MS Brose; R Elisei; J Capdevila; AO Hoff; MI Hu; M Tahara; B Robinson; M Gao; M Xia; P Maeda; E Sherman. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer.Future Oncol.18 - 28, pp. 3143 - 3150. 01/09/2022.
- A Garcia-Alvarez; J Hernando; A Carmona-Alonso; J Capdevila. What is the status of immunotherapy in thyroid neoplasms?. Front Endocrinol (Lausanne). 5, 01/08/2022.
- S Rao; G Anandappa; J Capdevila; L Dahan; L Evesque; S Kim; MP Saunders; DC Gilbert; LH Jensen; E Samalin; KL Spindler; A Demols; MG Guren; D Arnold; M Fakih; T Kayyal; M Cornfeld; C Tian; M Catlett; M Smith; JP Spano. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).ESMO Open.7 - 4, 08/2022.
- AB Apolo; C Porta; J Capdevila; S Viteri; C Rodriguez-Antona; L Martin; P Maroto. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review. Ther Adv Med Oncol.30/07/2022.
- P Maroto; C Porta; J Capdevila; AB Apolo; S Viteri; C Rodriguez-Antona; L Martin; D Castellano. Cabozantinib for the treatment of solid tumors: a systematic review.Ther Adv Med Oncol.14, 13/07/2022.
- J Capdevila; MA Gómez; M Guillot; D Páez; C Pericay; MJ Safont; N Tarazona; R Vera; J Vidal; J Sastre. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021).Clin Transl Oncol.24 - 7, pp. 1443 - 1444. 01/07/2022.
- EA Dijkstra; GAP Hospers; EM Kranenbarg; J Fleer; AGH Roodvoets; RR Bahadoer; MG Guren; JJJ Tjalma; H Putter; RMPH Crolla; MP Hendriks; J Capdevila; C Radu; CJH Van de Velde; PJ Nilsson; B Glimelius; B Van Etten; CAM. Marijnen. Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer - The RAPIDO trial.Radiother Oncol. 171, pp. 69 - 76. 06/2022.
- J Capdevila; M Ducreux; R García Carbonero; E Grande; T Halfdanarson; M Pavel; S Tafuto; S Welin; V Valentí; R Salazar. STREPTOZOTOCIN. 1982-2022: FORTY YEARS FROM THE FDA'S APPROVAL TO TREAT PANCREATIC NEUROENDOCRINE TUMORS.Neuroendocrinology.10/05/2022.
- J Capdevila; A Awada; D Führer-Sakel; S Leboulleux; P Pauwels. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.Cancer Treat Rev.01/05/2022.
- J Capdevila; A Klochikhin; S Leboulleux; P Isaev; C Badiu; B Robinson; BGM Hughes; B Keam; F Parnis; R Elisei; P Gajate; HK Gan; E Kapiteijn; L Locati; M Mangeshkar; L Faoro; J Krajewska; B. Jarzab. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.Thyroid.32 - 5, pp. 515 - 524. 05/2022
- JL Muñoz de Nova; J Hernando; M Sampedro Núñez; GT Vázquez Benítez; EM Triviño Ibáñez; MI Del Olmo García; J Barriuso; J Capdevila; E Martín-Pérez. Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy.World J Gastroenterol.28 - 13, pp. 1304 - 1314. 07/04/2022
- J Capdevila; E Grande; R García-Carbonero; M Simó; MI Del Olmo-García; P Jiménez-Fonseca; A Carmona-Bayonas; V Pubul. Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy.Oncologist. 27 - 4, pp. e328 - e339. 05/04/2022.
- A Garcia-Alvarez; JH Cubero; J Capdevila. What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?. Curr Oncol Rep.24 - 4, pp. 451 - 461. 01/04/2022.
- JK Ramage; E Friend; J Randell; B King; P Fernandez Ortega; MG McNamara; G Kaltsas; M Falconi; J Cwikla; J Capdevila; S Grozinsky-Glasberg; D Mandair; E Gamper; R Srirajaskanthan; M O Weickert; D Gray. Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module). J Neuroendocrinol.34 - 4, pp. e13097. 04/2022.
- RA Toledo; C Jimenez; G Armaiz-Pena; C Arenillas; J Capdevila; PLM. Dahia. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.Endocr Rev.44 - 2, pp. 312 - 322. 04/03/2022.
- J Hernando; J Riera-Arnau; M Roca; A Garcia; J Capdevila. Cervical dissecting extravasation of oxaliplatin: A case report.Mol Clin Oncol.16 - 3, pp. 60. 01/03/2022.
- N Fazio; L Gervaso; TR Halfdanarson; A La Salvia; J Hofland; J Hernando; MB Sonbol; R Garcia-Carbonero; J Capdevila; WW de Herder; A Koumarianou; G Kaltsas; M Rossi; S Grozinsky-Glasberg; K Oleinikov; S Boselli; D Tamayo; V Bagnardi; A Laffi; M Rubino; F Spada. Corrigendum to 'Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study' [European Journal of Cancer 154 (2021) 246-252]. Eur J Cancer.160, pp. 289 - 290. 01/01/2022
- P Jimenez-Fonseca; A Carmona-Bayonas; A Lamarca; J Barriuso; A Castaño; M Benavent; V Alonso; MDC Riesco; T Alonso-Gordoa; A Custodio; M Sanchez Canovas; J Hernando; C López; A La Casta; A Fernandez Montes; M Marazuela; G Crespo; JA Diaz; E Feliciangeli; J Gallego; M Llanos; A Segura; F Vilardell; JC Percovich; E Grande; J Capdevila; J Valle; R Garcia-Carbonero. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.Neuroendocrinology.112 - 1, pp. 88 - 100. 01/01/2022.
- M Wurm; O Schaaf; K Reutner; R Ganesan; S Mostböck; C Pelster; J Böttcher; B de Andrade Pereira; C Taubert; I Alt; G Serna; A Auguste; KB Stadermann; D Delic; F Han; J Capdevila; PG Nuciforo; R Kroe-Barrett; PJ Adam; AB Vogt; I Hofmann. A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway. Mol Cancer Ther.20 - 11, pp. 2250 - 2261. 01/11/2021.
- N Fazio; L Gervaso; TR Halfdanarson; A La Salvia; J Hofland; J Hernando; MB Sonbol; R Garcia-Carbonero; J Capdevila; WW de Herder; A Koumarianou; G Kaltsas; M Rossi; S Grozinsky-Glasberg; K Oleinikov; S Boselli; D Tamayo; V Bagnardi; A Laffi; M Rubino; F Spada. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study.Eur J Cancer.154, pp. 246 - 252. 01/09/2021.
- MS Brose; B Robinson; SI Sherman; J Krajewska; CC Lin; F Vaisman; AO Hoff; E Hitre; DW Bowles; J Hernando; L Faoro; K Banerjee; JW Oliver; B Keam; J Capdevila. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol.22 - 8, pp. 1126 - 1138. 01/08/2021.
- J Capdevila; N Fazio; C Lopez; A Teulé; JW Valle; S Tafuto; A Custodio; N Reed; M Raderer; E Grande; R Garcia-Carbonero; P Jimenez-Fonseca; J Hernando; A Bongiovanni; F Spada; V Alonso; L Antonuzzo; A Spallanzani; A Berruti; A La Casta; I Sevilla; P Kump; D Giuffrida; X Merino; L Trejo; P Gajate; I Matos; A Lamarca;
- T Ibrahim. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).J Clin Oncol.39 - 20, pp. 2304 - 2312. 10/07/2021
- Adrenal Cancer Treatment
- Bile Duct Cancer Treatment
- Cancer/Oncology Consultation
- Colorectal Cancer
- Gastrointestinal Cancer
- Immunotherapy
- Liver Cancer Treatment
- Medical Oncology
- Neuroendocrine Tumours
- Pancreatic Cancer Treatment
- Pheochromocytoma
- Small Intestine Cancer Treatment
- Systemic Chemotherapy
- Targeted Therapy
- Thyroid Cancer Treatment
- European Organisation for Research and Treatment of Cancer (EORTC)
- European Society for Medical Oncology (ESMO)
- European Neuroendocrine Tumor Society (ENETS)
- American Society of Clinical Oncology (ASCO)
- Multidisciplinary Spanish Group of Digestive Cancer (GEMCAD)
- Spanish Cooperative Group for Digestive Tumor Therapy (TTD)